AFMDQ (Affimed NV) Non Operating Income: $4.25 Mil (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AFMDQ Affimed NV AFMDQ
16 GF Score
Price $0.00
View Full Analysis

What is Affimed NV Non Operating Income?

Affimed NV AFMDQ 16 Non Operating Income is $4.25 Mil as of Sep. 2024. GuruFocus rates AFMDQ with a GF Score™ of 16/100.

Non Operating Income is income or expense that comes from miscellaneous sources. Affimed NV's Non Operating Income for the three months ended in Sep. 2024 was $-0.83 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $4.25 Mil.

Affimed NV Non Operating Income Related Terms

Affimed NV Non Operating Income Historical Data

* Premium members only.

The historical data trend for Affimed NV's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV Non Operating Income Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 -7.80 9.72 4.49 5.41

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 4.28 0.57 0.24 -0.83
AFMDQ
16GF Score
Affimed NV AFMDQ
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Affimed NV Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $4.25 Mil mean?
Affimed NV (AFMDQ) has a Non Operating Income of $4.25 Mil as of Sep. 2024. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Affimed NV and its competitors.
Is Affimed NV's Non Operating Income too high?
Affimed NV's current Non Operating Income is $4.25 Mil. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's Non Operating Income compare to SYRS and BTAX?
Affimed NV's Non Operating Income of $4.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Affimed NV and its competitors. Affimed NV's current Non Operating Income is $4.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current Non Operating Income of $4.25 Mil. The current Non Operating Income is $4.25 Mil. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current Non Operating Income is $4.25 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Affimed NV Business Description

Address Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score

Get the complete analysis for AFMDQ

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price